Avid Bioservices, Inc. CDMO
12.49 0.00 (+0.00%)
At closeFeb 4, 2025, 4:00 PM EST
12.49 Day range 12.49
52-week range unavailable
- YTD
- +1.13%
- 1 year
- +55.16%
- Market cap
- 784.83M
- Revenue (ttm)
- 142.36M
- Profit margin
- -101.27%
- Shares out
- 63.96M
- Forward P/E
- -175.29
- YTD return
- +1.13%
- 1-year return
- +55.16%
- Open
- 12.49
- Previous close
- 12.49
- Day's range
- 12.49 – 12.49
- Beta
- 1.41
- Analysts
- Hold
- Price target
- 12.88 (+3.1%)
2Y -4.82 (-27.85%)
Key statistics
- Enterprise value
- 955.97M
- PEG ratio
- 0.00
- Price / sales
- 5.51
- Price / book
- 12.81
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 6.50%
- Free cash flow
- -201.63K
- Total cash
- 36.78M
- Total debt
- 207.43M
- Return on equity
- -115.84%
- Short % of float
- 18.40%
- 50-day average
- 11.50
- 200-day average
- 9.42
Analyst view
Consensus: hold
Hold
Price target (mean) 12.88 +3.1% upside
Now 12.49
- Target (low)
- 12.50
- Target (mean)
- 12.88
- Target (high)
- 14.00
Ratings (0m) 5 1 buy · 4 hold · 0 sell
- Strong buy0
- Buy1
- Hold4
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.04.
Financials — quick view
CDMO Revenue — quarterly 33.48M
CDMO Net income — quarterly -17.41M
CDMO EPS — quarterly -0.27
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 10, 2024 | Oct 1, 2024 | -0.09 | -0.22 | -0.13 | -144.44% |
| Sep 9, 2024 | Jul 1, 2024 | -0.04 | -0.03 | +0.01 | +25.00% |
| Jul 2, 2024 | Apr 1, 2024 | 0.03 | -0.07 | -0.10 | -333.33% |
| Apr 24, 2024 | Jan 1, 2024 | -0.02 | -0.08 | -0.06 | -300.00% |
| Dec 7, 2023 | Oct 1, 2023 | -0.09 | -0.12 | -0.03 | -33.33% |
| Sep 7, 2023 | Jul 1, 2023 | -0.04 | 0.00 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 7, 2024 | RBC Capital | down | Outperform | Sector Perform |
| Nov 7, 2024 | William Blair | reit | — | Market Perform |
| Sep 10, 2024 | RBC Capital | main | Outperform | Outperform |
| Sep 10, 2024 | Stephens & Co. | reit | Overweight | Overweight |
| Sep 10, 2024 | William Blair | reit | — | Market Perform |
| Jul 3, 2024 | RBC Capital | reit | Outperform | Outperform |
About Avid Bioservices, Inc.
Avid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is based in Tustin, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- avidbio.com
News
Kimball Electronics, Inc. Announces Date For Reporting First Quarter Fiscal Year 2027 Financial Results 
Samsung Biologics Reports Third Quarter 2026 Financial Results 
Scinai CEO Updates Shareholders on CDMO Growth and Extended Runway Following Completed Financing 
With Section 232 Tariffs Reshaping Biotech, Valion Bio's Velocity Bioworks Capitalizes on Domestic CDMO Surge 
Scinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing Agreement 
BioHarvest Advances Proprietary Olive Cell Asset to Commercial Readiness, Opening New CDMO Licensing Opportunity 
Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies 
Piramal Pharma Solutions Advances Sustainability Efforts with Solar Power Plant Addition at Morpeth, UK Site 
Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business 
Samsung Biologics publishes prospectus for PolyPeptide public tender offer
Your note
Sign in to keep a note on CDMO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALEGRIA ESTHER M | Director | Conversion of Exercise of derivative security | Dec 12, 2024 | 37,746 |
| CARLEONE JOSEPH | Director | Conversion of Exercise of derivative security | Dec 12, 2024 | 130,324 |
| GREEN NICHOLAS STEWART | Chief Executive Officer | Sale | Oct 9, 2024 | 226,653 |
| HANCOCK RICHARD BROOKE | Director | Conversion of Exercise of derivative security | Dec 12, 2024 | 144,319 |
| HART DANIEL RYAN | Chief Financial Officer | Sale | Apr 29, 2024 | 82,221 |
| KWIETNIAK MATTHEW R | Officer | Sale | Oct 13, 2024 | 25,407 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.22% | 5,259,199 | 64.53M | Sep 29, 2024 |
| Millennium Management Llc | 6.55% | 4,189,003 | 51.40M | Sep 29, 2024 |
| Vanguard Group Inc | 6.01% | 3,846,383 | 47.20M | Sep 29, 2024 |
| Point72 Asset Management, L.P. | 5.97% | 3,815,806 | 46.82M | Sep 29, 2024 |
| AltraVue Capital, LLC | 5.94% | 3,797,813 | 46.60M | Sep 29, 2024 |
| State Street Corporation | 4.69% | 3,002,503 | 36.84M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.20% | 2,048,596 | 25.14M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.48% | 1,584,621 | 19.44M | Oct 30, 2024 |
| Fidelity Strategic Advisors Small-Mid Cap Fund | 2.10% | 1,344,470 | 16.50M | Jul 30, 2024 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 2.06% | 1,315,453 | 16.14M | Sep 29, 2024 |
| Fidelity Rutland Square Tr II-Strategic Advisers U.S. Total Stock Fd | 1.76% | 1,125,676 | 13.81M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.55% | 988,820 | 12.13M | Sep 29, 2024 |